Litigation Details for UNITED THERAPEUTICS CORPORATION v. SANDOZ, INC. (D.N.J. 2012)

UNITED THERAPEUTICS CORPORATION v. SANDOZ, INC. (D.N.J. 2012)

Docket		Date Filed	2012-03-14
Court	District Court, D. New Jersey	Date Terminated	2014-08-29
Cause	35:145 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Lois H. Goodman
Parties	SANDOZ, INC.
Patents	6,765,117; 7,999,007
Attorneys	STEPHEN M. ORLOFSKY
Firms	Christina Lynn Saveriano
Link to Docket	External link to docket

Details for UNITED THERAPEUTICS CORPORATION v. SANDOZ, INC. (D.N.J. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-03-14				External link to document

United Therapeutics v. Sandoz, 3:12-cv-01617: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

United Therapeutics Corporation sued Sandoz Inc. in the U.S. District Court for the District of New Jersey after Sandoz filed an abbreviated new drug application seeking approval for a generic treprostinil product. The dispute centered on United Therapeutics’ inhaled-treprostinil patent estate, particularly U.S. Patent No. 8,318,802. The litigation challenged whether United Therapeutics could block generic entry based on method-of-treatment claims covering inhaled treprostinil for pulmonary hypertension.

The case is commercially important because it tested the enforceability of patent protection for Tyvaso, United Therapeutics’ inhaled treprostinil product. The principal patent claims were ultimately held invalid for obviousness, removing a major patent barrier to generic competition.

What drug and patent were at issue in United Therapeutics v. Sandoz?

The case involved treprostinil, a prostacyclin analogue used to treat pulmonary arterial hypertension. United Therapeutics markets treprostinil products under the Remodulin, Tyvaso and Orenitram brands.

The litigation focused primarily on inhaled treprostinil and Tyvaso-related patent rights. U.S. Patent No. 8,318,802, titled "Methods of Treating Pulmonary Hypertension," claimed methods involving administration of treprostinil by inhalation to patients with pulmonary hypertension.[1]

Item	Details
Plaintiff	United Therapeutics Corporation
Defendant	Sandoz Inc.
Court	U.S. District Court for the District of New Jersey
Case number	3:12-cv-01617
Active ingredient	Treprostinil
Relevant product	Tyvaso, inhaled treprostinil
Principal patent	U.S. Patent No. 8,318,802
Patent issue date	Nov. 27, 2012
Primary legal issue	Obviousness of inhaled-treprostinil treatment claims
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act

What patents protect Tyvaso and inhaled treprostinil?

The central patent in this litigation was U.S. Patent No. 8,318,802. The patent covered treatment of pulmonary hypertension using inhaled treprostinil formulations. Its claims addressed the therapeutic method rather than merely the chemical structure of treprostinil.

The patent estate surrounding Tyvaso has included several types of protection:

Method-of-use patents

Method patents cover administering treprostinil by inhalation to treat pulmonary hypertension. These patents are exposed to invalidity challenges based on earlier clinical disclosures, product labels, published studies and known uses of treprostinil.

Formulation patents

Formulation patents may cover concentrations, excipients, pH, stability characteristics and delivery properties of inhaled treprostinil solutions. These rights can provide protection after broad method claims are invalidated, but their scope depends on the exact formulation used by a generic applicant.

Device and delivery patents

Tyvaso is administered through a specialized inhalation system. Device patents may cover nebulizer components, dosing systems and delivery methods. A device patent can create a separate infringement issue even when a generic formulation does not infringe the composition or method claims.

Manufacturing patents

Treprostinil manufacturing patents can cover intermediates, synthetic routes, purification methods and salt forms. These rights generally create a higher barrier for generic manufacturers when the claimed process is required to produce the active ingredient or final drug substance.

The Sandoz litigation is principally associated with the inhaled-treatment claims of the '802 patent. It did not establish that every patent relating to treprostinil, Tyvaso or the Tyvaso delivery system was invalid.

What was Sandoz’s Paragraph IV challenge?

Sandoz pursued FDA approval through an ANDA and made a Paragraph IV certification against United Therapeutics’ patent rights. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

United Therapeutics responded by filing a patent-infringement action. Under the Hatch-Waxman framework, the filing of the action generally triggered a 30-month stay of FDA approval, subject to statutory exceptions and court developments.[2]

The dispute therefore had two separate dimensions:

1. Whether Sandoz’s ANDA product infringed the asserted claims.
2. Whether United Therapeutics’ claims were valid and enforceable.

The decisive issue was validity. The court concluded that the asserted inhaled-treprostinil claims were obvious in view of the prior art.

Why did the court find the inhaled-treprostinil claims obvious?

The obviousness analysis examined whether a person of ordinary skill would have been motivated to administer treprostinil through inhalation and would have had a reasonable expectation of success.

The relevant prior art included information concerning:

• Treprostinil as a known pulmonary vasodilator.
• The use of prostacyclin analogues in pulmonary hypertension.
• Inhaled delivery as a route for pulmonary vasodilator therapy.
• Treprostinil’s pharmacological properties.
• Earlier disclosures concerning inhaled prostacyclin treatment.
• The potential clinical advantages of pulmonary delivery, including localized administration and reduced systemic exposure.

The court treated the claimed combination of treprostinil and inhalation as an obvious application of known therapeutic and delivery principles. The fact that the product later achieved commercial success did not overcome the prior-art showing.

The Federal Circuit’s review confirmed the invalidity determination. The appellate analysis focused on the relationship between the known properties of treprostinil, the known use of inhaled prostacyclin therapy and the motivation to pursue inhaled administration for pulmonary hypertension.[3]

What was the litigation outcome?

The asserted claims of U.S. Patent No. 8,318,802 were held invalid for obviousness. The judgment eliminated the patent as an enforceable basis for blocking Sandoz’s ANDA product.

Litigation stage	Outcome
District court validity ruling	Asserted claims held invalid for obviousness
Infringement consequence	No enforceable patent liability based on invalid claims
Appellate review	Invalidity determination affirmed
Commercial consequence	Reduced patent protection for inhaled treprostinil based on the asserted method claims

The ruling was narrower than a declaration that all Tyvaso patents were invalid. It addressed the asserted claims and the record developed in the Sandoz case.

When did the Tyvaso patent protection lose exclusivity?

The '802 patent ceased to provide effective exclusivity after the invalidity judgment became final. A patent can remain unexpired on its face while providing no practical exclusion against the accused product if the asserted claims have been held invalid.

This distinction is important:

Concept	Effect
Patent expiration	Rights end by passage of the patent term
Patent invalidity	Asserted claims cannot be enforced even before scheduled expiration
FDA regulatory exclusivity	Independent of patent validity
ANDA approval stay	Can end through statutory timing or litigation resolution
Settlement launch date	May establish a negotiated commercial entry date

The '802 litigation therefore shortened the effective life of the patent compared with its nominal term. The invalidity judgment, rather than ordinary expiration, was the key event for this case.

What was the FDA and Orange Book significance?

Tyvaso was approved by the FDA in 2009 as an inhaled treprostinil product. The ANDA dispute arose within the FDA’s Hatch-Waxman framework, which permits a generic applicant to challenge listed patents through Paragraph IV certification.[4]

Orange Book status must be analyzed patent by patent. The case did not automatically invalidate every patent listed for Tyvaso, nor did it eliminate any separate regulatory exclusivity period. The principal effect was on the enforceability of the asserted inhaled-treatment patent.

For commercial diligence, the relevant distinctions are:

• FDA approval of Tyvaso does not itself establish patent validity.
• Orange Book listing does not create a presumption that a patent will survive litigation.
• A Paragraph IV suit can delay approval but cannot preserve an invalid patent.
• A method-of-use patent may be vulnerable even when the active ingredient and formulation remain protected by other rights.
• A generic applicant may obtain approval with labeling designed to omit patented uses, subject to the scope of the remaining patent claims and the applicable FDA rules.

How strong was United Therapeutics’ patent estate after the Sandoz decision?

The decision materially weakened United Therapeutics’ broad method-of-use position for inhaled treprostinil. It did not necessarily eliminate narrower protection based on formulation, device, dosing regimen or manufacturing technology.

Strengths

United Therapeutics retained several potential sources of commercial protection:

• Brand recognition and established physician use.
• Clinical and regulatory experience with treprostinil.
• Potential formulation and device patents.
• Manufacturing know-how.
• Product-specific safety and efficacy data.
• A broad portfolio covering multiple treprostinil dosage forms.

Weaknesses

The litigation exposed vulnerabilities in broad method claims where:

• The active ingredient was already known.
• Pulmonary hypertension treatment was already established.
• Inhaled prostacyclin therapy was disclosed or suggested.
• The claimed route of administration produced expected therapeutic benefits.
• Commercial success was not sufficiently linked to the claimed invention.

The case demonstrates that a patent claiming a known drug delivered through a known route may face substantial obviousness risk unless the claims include a specific, unexpected technical result or a narrowly defined dosing or formulation limitation.

What generic entry risks existed for Tyvaso?

The invalidity judgment increased generic-entry risk, but it did not guarantee immediate market entry. A generic applicant still needed FDA approval and had to address any surviving patents or regulatory barriers.

The principal entry scenarios were:

Immediate entry after approval

If no enforceable patent remained and the ANDA received FDA approval, Sandoz could potentially launch subject to ordinary regulatory and commercial conditions.

Delayed entry based on other patents

United Therapeutics could rely on separate formulation, device, manufacturing or method patents if those patents were listed and asserted against the ANDA product.

Carve-out or skinny-label entry

A generic applicant could seek approval with a label omitting a patented indication or method, depending on the FDA-approved labeling and the scope of the remaining patent claims.

Settlement-based entry

A settlement could establish a negotiated launch date, licensing arrangement or restrictions on the generic product. The publicly reported outcome of the case should be distinguished from later settlements involving other treprostinil products or other generic manufacturers.

Which companies challenged United Therapeutics’ treprostinil products?

Sandoz was one of the companies involved in patent challenges against United Therapeutics’ treprostinil franchise. Other generic manufacturers have pursued or evaluated opportunities involving treprostinil injection, inhaled treprostinil and related dosage forms.

Competitive analysis must separate:

• Remodulin, an injectable treprostinil product.
• Tyvaso, an inhaled treprostinil solution.
• Tyvaso DPI, a dry-powder inhaled product.
• Orenitram, an oral extended-release treprostinil product.

Patent outcomes for one dosage form do not automatically determine the risk profile for the others. Inhaled products also raise device and delivery-system issues that do not apply in the same way to injectable or oral products.

What patent litigation affects United Therapeutics’ revenue exposure?

Tyvaso has been a major commercial product for United Therapeutics, and loss of broad patent protection increases the risk of price erosion, formulary substitution and market-share loss. The revenue impact depends on:

• The timing of FDA approval for competing products.
• Whether a generic uses the same inhalation device.
• Whether separate patents remain enforceable.
• The availability of Tyvaso DPI as a differentiated product.
• Prescriber and payer acceptance of the generic.
• Manufacturing capacity and supply reliability.
• Any authorized-generic or settlement arrangement.

The Sandoz decision primarily affected the legal barrier to generic inhaled treprostinil. It did not itself determine the timing, pricing or market penetration of a generic product.

What geographic patent coverage applied?

The case was a U.S. action under the Hatch-Waxman statute. Its judgment directly affected U.S. patent enforcement and the U.S. ANDA pathway.

It did not invalidate corresponding foreign patents. United Therapeutics’ protection in Europe, Canada, Japan and other markets required separate analysis of:

• National patent grants.
• Patent-term adjustments and extensions.
• Supplementary protection certificates.
• Local validity standards.
• National regulatory exclusivity.
• Local litigation or opposition proceedings.

A U.S. invalidity ruling cannot be used as a direct substitute for foreign freedom-to-operate analysis.

How does the Sandoz case compare with other treprostinil patent risks?

Product	Main patent-risk categories	Principal generic risk
Tyvaso	Method, formulation, device and dosing patents	High if broad method claims fail and no narrow patent blocks entry
Tyvaso DPI	Device, formulation, manufacturing and delivery patents	Potentially more complex because of dry-powder technology
Remodulin	Composition, formulation, manufacturing and method patents	Injectable competition may develop separately
Orenitram	Extended-release formulation and manufacturing patents	Formulation and process claims are central

The Sandoz decision is most relevant to broad inhaled-treprostinil method claims. It is less predictive of disputes involving controlled-release oral tablets, injectable formulations or dry-powder delivery systems.

Key Takeaways

• United Therapeutics sued Sandoz in the District of New Jersey over an ANDA for a generic treprostinil product.
• The central patent was U.S. Patent No. 8,318,802, covering inhaled treprostinil treatment for pulmonary hypertension.
• The asserted claims were held invalid for obviousness.
• The ruling weakened United Therapeutics’ broad method-of-use protection for Tyvaso-related inhaled treprostinil therapy.
• The decision did not invalidate every United Therapeutics patent covering Tyvaso, treprostinil, Tyvaso DPI, Remodulin or Orenitram.
• Remaining generic-entry risks include formulation, device, dosing, manufacturing and separate method patents.
• The U.S. judgment does not determine patent validity or regulatory exclusivity in foreign jurisdictions.
• Tyvaso revenue exposure depends on FDA approval timing, surviving patents, generic labeling, device compatibility and commercial adoption.

FAQs About United Therapeutics v. Sandoz

Did United Therapeutics win or lose the Sandoz patent case?

United Therapeutics lost on the validity issue concerning the asserted inhaled-treprostinil claims. The claims were held invalid for obviousness, and the invalidity determination was affirmed on appeal.

Was U.S. Patent No. 8,318,802 a composition patent?

No. The '802 patent primarily covered methods of treating pulmonary hypertension using inhaled treprostinil. Its protection differed from a patent claiming the treprostinil molecule itself.

Did the ruling authorize a generic Tyvaso launch automatically?

No. Patent invalidity removed one barrier, but FDA approval, any surviving patents, product labeling and commercial manufacturing requirements remained relevant.

Could United Therapeutics enforce other Tyvaso patents after the Sandoz decision?

Yes. The decision was limited to the asserted claims and did not automatically invalidate separate formulation, device, manufacturing or dosing patents.

Does the Sandoz decision affect Remodulin and Orenitram patents?

Not directly. Remodulin and Orenitram use different dosage forms and may rely on different patent claims. Their patent and generic-entry risks require separate analysis.

References

1. United States Patent and Trademark Office. (2012). U.S. Patent No. 8,318,802: Methods of treating pulmonary hypertension.
2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Court of Appeals for the Federal Circuit. (n.d.). United Therapeutics Corporation v. Sandoz, Inc., appellate proceedings arising from No. 3:12-cv-01617.
4. United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).